EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and/or Recurrent Head and Neck Squamous Cell Carcinoma

Nanami L Miyazaki, Aki Furusawa iD, Peter L Choyke iD, Hisataka Kobayashi iD

Cancers · 24.10.2023 · 15 (21) · 5117

DOI: 10.3390/cancers15215117 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.10.2023. Verfasst von Nanami L Miyazaki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NCI NIH HHS, National Institutes of Health, National Cancer Institute, Center for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Head and neck squamous cell carcinoma (HNSCC) contribute to a significant global cancer burden. Developments in current therapeutic approaches have improved patient outcomes but have limited efficacy in patients with unresectable and/or recurrent HNSCC. RM-1929 near-infrared photoimmunotherapy (NIR-PIT) is an emerging treatment that is currently being investigated in a Phase III clinical trial and has been conditionally approved for the treatment of unresectable and/or recurrent HNSCC in Japan. Here, we collect a series of case reports and clinical trial data to assess the efficacy of RM-1929 NIR-PIT. Disease control rates ranged from 66.7 to 100% across these studies, and overall response rates ranged from 43.3 to 100%, suggesting positive clinical outcomes. Low-grade postoperative localized pain and edema were the most frequently reported side effects, and preliminary reports on quality of life and pain levels suggest that RM-1929 NIR-PIT does not significantly decrease quality of life and is manageable with existing pain management strategies, including opioids. These preliminary data in real-world use of RM-1929 NIR-PIT show that it is a well-tolerated therapy that has clinically meaningful outcomes for patients with unresectable and/or recurrent HNSCC.

Schlagwörter

Stichwörter der Autor:innen

RM-1929cetuximab sarotalocan sodiumcetuximab-IR700photoimmunotherapyrecurrent head and neck squamous cell carcinoma (HNSCC)

Autor:innen und Institutionen

  • Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

ORCID-Profile: Aki Furusawa, Peter L Choyke, Hisataka Kobayashi

Förderung

  • Intramural NIH HHS
  • NCI NIH HHS
  • National Institutes of Health, National Cancer Institute, Center for Cancer Research

Zitieren

APA

Miyazaki, N. L., Furusawa, A., Choyke, P. L., & Kobayashi, H. (2023). Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and/or Recurrent Head and Neck Squamous Cell Carcinoma. Cancers, 15(21), 5117. https://doi.org/10.3390/cancers15215117

Vancouver

Miyazaki NL, Furusawa A, Choyke PL, Kobayashi H. Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and/or Recurrent Head and Neck Squamous Cell Carcinoma. Cancers. 2023;15(21):5117. doi:10.3390/cancers15215117

BibTeX
@article{Miyazaki2023,
  author = {Miyazaki, Nanami L and Furusawa, Aki and Choyke, Peter L and Kobayashi, Hisataka},
  title = {Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and/or Recurrent Head and Neck Squamous Cell Carcinoma},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {21},
  pages = {5117},
  doi = {10.3390/cancers15215117}
}
Kostenlos starten →